

Special Issue

Lymphatic Function and Dysfunction: From Physiopathology to Therapy

Message from the Guest Editor

The Special Issue “Lymphatic Function and Dysfunction: From Physiopathology to Therapy” aims to be a platform for researchers to showcase their cutting-edge research, systematic reviews and meta-analyses on the following topics (not an exhaustive list): Basic research on physiology of normal lymphatic function and dysfunction; Primary lymphedema; Secondary lymphedema due to cancer, cancer treatment, obesity, wounds, injury, and trauma; Lymphatic function and immune; Fluid homeostasis, fluid overload, and symptoms related to fluid accumulation in cardiovascular diseases (heart failure, hypertension, stroke, etc.); Lymphatic function and wound healing; Lymphatic function and Alzheimer’s disease; Lymphatic function and metabolic syndrome; Lymphatic function and cancer and tumor metastasis; Lymphatic pain, chronic pain, and myofascial pain; Therapeutic exercises targeting lymphatic function for lymphedema, fluid overload, lymphatic pain, chronic pain, and symptoms related to fluid accumulation; Complementary and integrative therapy for lymphatic dysfunction (e.g., lymphedema, fluid overload, lymphatic pain), chronic pain, and symptoms related to fluid accumulation.

Guest Editor

Prof. Dr. Mei Rosemary Fu

School of Nursing, Rutgers University, The State University of New Jersey, Camden, NJ 08102, USA

Deadline for manuscript submissions

closed (15 July 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/107051

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).